Detailed price information for Compass Gold Corporation (CVB-X) from The Globe and Mail including charting and trades.
Disease-free survival improved with durvalumab plus BCG induction/maintenance versus BCG alone, reducing recurrence/progression/death risk (HR 0.68; p=0.0154) with median DFS not reached. Eligibility ...
MedPage Today on MSN
No Prostate Cancer Survival Benefit With More Extensive Lymph Node Assessment
Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...
A study published in Ophthalmology and Therapy found that Epioxa, an epithelium-on corneal collagen cross-linking treatment, ...
AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been ...
Pieter Martens, MD, PhD (Hospital Oost-Limburg, Genk, Belgium), who made the “pro” case on behalf of IV iron, pointed out ...
EU Committee recommends approval of AstraZeneca’s camizestrant for 1st-line advanced ER-positive breast cancer: Cambridge, UK Monday, May 25, 2026, 09:00 Hrs [IST] AstraZenecas ...
Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026, the annual congress of the Heart ...
Newspoint on MSN
Building a realistic path into data science in 2026
Data science has an unusual marketing problem. The role is consistently described using its most glamorous applications — ...
VMPLMumbai (Maharashtra) [India], May 21: Astellas Pharma India today announced that PADCEV™ (enfortumab vedotin) in combination with pembrolizumab is now approved for the first-line treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results